REGENERON PHARMACEUTICALS's ticker is and the CUSIP is 75886F957. A total of 6 filers reported holding REGENERON PHARMACEUTICALS in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,578,840 | -62.0% | 16,500 | -66.8% | 0.01% | -63.6% |
| Q2 2023 | $35,711,438 | +15.6% | 49,700 | +32.2% | 0.03% | -8.3% |
| Q1 2023 | $30,894,792 | +92.9% | 37,600 | +69.4% | 0.04% | +44.0% |
| Q4 2022 | $16,017,078 | -11.3% | 22,200 | -15.3% | 0.02% | +8.7% |
| Q3 2022 | $18,048,000 | +20.6% | 26,200 | +10.5% | 0.02% | +91.7% |
| Q4 2021 | $14,967,000 | +5.5% | 23,700 | -6.7% | 0.01% | -29.4% |
| Q2 2021 | $14,187,000 | -33.2% | 25,400 | -43.4% | 0.02% | -45.2% |
| Q1 2021 | $21,244,000 | -39.8% | 44,900 | -38.6% | 0.03% | -31.1% |
| Q4 2020 | $35,315,000 | +79.7% | 73,100 | +108.3% | 0.04% | +45.2% |
| Q3 2020 | $19,648,000 | -20.0% | 35,100 | -10.9% | 0.03% | -38.0% |
| Q2 2020 | $24,572,000 | -1.9% | 39,400 | -23.2% | 0.05% | -5.7% |
| Q1 2020 | $25,049,000 | +28.8% | 51,300 | -1.0% | 0.05% | +6.0% |
| Q4 2019 | $19,450,000 | +435.2% | 51,800 | +295.4% | 0.05% | +354.5% |
| Q3 2019 | $3,634,000 | -55.9% | 13,100 | -50.2% | 0.01% | -59.3% |
| Q2 2019 | $8,232,000 | +5.5% | 26,300 | +38.4% | 0.03% | -3.6% |
| Q1 2019 | $7,802,000 | -13.7% | 19,000 | -21.5% | 0.03% | 0.0% |
| Q4 2018 | $9,039,000 | – | 24,200 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMC-Chicago, LLC | 73,100 | $35,315,000 | 0.04% |
| GROUP ONE TRADING, L.P. | 46,700 | $22,561,000 | 0.04% |
| SIMPLEX TRADING, LLC | 365 | $17,633,000 | 0.02% |
| SG Americas Securities, LLC | 19,200 | $2,212,000 | 0.01% |
| JPMORGAN CHASE & CO | 22,500 | $10,870,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |